Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

XmAb2513

Monoclonal antibody · Immune activation, directed at CD30 (TNFRSF8) · developed by Xencor

Phase 1 Most advanced trial (none active)
XNCR Developer
1 Registered trials

What is XmAb2513?

XmAb2513 is a humanized monoclonal antibody that binds the CD30 receptor, a member of the tumor necrosis factor receptor superfamily expressed on certain lymphoma cells. It is being studied in Hodgkin lymphoma and anaplastic large cell lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Monoclonal antibody
Targets
CD30 (TNFRSF8)
Mechanism
Immune activation, directed at CD30 (TNFRSF8)
Pathways
cytotoxic T lymphocyte response
Therapy area
Oncology
Developer
Xencor, Inc. (XNCR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
33VWC847G8

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00606645 Phase 1 Hodgkin Lymphoma Completed XNCR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Anaplastic Large Cell LymphomaHodgkin Lymphoma

Other drugs acting on TNFRSF8

More from Xencor

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the XNCR page.

Follow XNCR, the company behind XmAb2513

See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XNCR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.